• 1. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 2. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 3. Enantiomeric helical TiO2 nanofibers modulate different peptide assemblies and subsequent cellular behaviors?
  Xu Jie,Deng Xu,Weili Wei RSC Adv., 2019,9, 29149-29153
• 4. Distribution and ecological risk assessment of typical antibiotics in the surface waters of seven major rivers, China?
  Environ. Sci.: Processes Impacts, 2021,23, 1088-1100
• 5. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182

Recent Advances in the Application of Tert-butyl 4-(hydroxymethyl)-4-(trifluoromethyl)piperidine-1-carboxylate (CAS: 1260893-18-2) in Chemical Biology and Pharmaceutical Research

The compound Tert-butyl 4-(hydroxymethyl)-4-(trifluoromethyl)piperidine-1-carboxylate (CAS: 1260893-18-2) has recently emerged as a key intermediate in the synthesis of biologically active molecules, particularly in the development of novel pharmaceuticals targeting central nervous system (CNS) disorders and metabolic diseases. This piperidine derivative, characterized by its trifluoromethyl and hydroxymethyl functional groups, offers unique physicochemical properties that enhance drug-like characteristics, including improved metabolic stability and blood-brain barrier permeability.

Recent studies have highlighted the role of this compound in the synthesis of potent gamma-aminobutyric acid (GABA) receptor modulators. A 2023 publication in the Journal of Medicinal Chemistry demonstrated its utility as a building block for the development of next-generation anxiolytics with reduced side-effect profiles. The trifluoromethyl group, in particular, was shown to significantly enhance binding affinity to GABA-A receptor subtypes while the hydroxymethyl group facilitated further structural modifications.

In the field of protease inhibitor development, researchers at several major pharmaceutical companies have incorporated this piperidine derivative into novel scaffolds targeting viral proteases. The compound's structural flexibility allows for the introduction of various pharmacophores while maintaining optimal spatial orientation for target binding. A recent patent application (WO2023051234) describes its use in the synthesis of covalent inhibitors of SARS-CoV-2 main protease, showing promising in vitro activity against multiple variants of concern.

The synthetic accessibility of 1260893-18-2 has been significantly improved through recent methodological advances. A 2024 report in Organic Process Research & Development detailed a scalable, continuous-flow synthesis route that achieves >90% yield with excellent enantioselectivity. This development is particularly important as demand for the compound has increased substantially in both academic and industrial research settings.

From a medicinal chemistry perspective, the presence of both the hydroxymethyl and trifluoromethyl groups on the piperidine ring provides multiple vectors for structure-activity relationship (SAR) exploration. Computational studies published in late 2023 suggest that these functional groups participate in unique halogen bonding interactions with biological targets, potentially explaining the enhanced potency observed in several compound series derived from this intermediate.

Looking forward, the application of 1260893-18-2 appears poised for expansion into additional therapeutic areas. Preliminary data presented at the 2024 American Chemical Society National Meeting demonstrated its incorporation into novel radiopharmaceuticals for positron emission tomography (PET) imaging, leveraging the fluorine atoms for 18F-labeling. This dual utility as both a synthetic intermediate and potential imaging agent underscores the compound's growing importance in chemical biology and pharmaceutical research.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)